Welcome to our dedicated page for DOSED news (Ticker: DOSED), a resource for investors and traders seeking the latest updates and insights on DOSED stock.
The DOSED news page on Stock Titan provides coverage related to Doseology Sciences Inc., a biotechnology-driven consumer products company focused on IP-backed oral stimulant technologies and oral pouch products. News items reflect the company’s emphasis on scientific research, advanced formulation technologies, and preparation for regulated markets.
Readers can expect updates on Doseology’s progress in oral stimulant and oral pouch technologies, including developments in stimulant, nicotine, and nicotine-analogue pouch formats. Company announcements may highlight partnerships with regulatory science advisors, work on formulation strategy and data generation, and steps toward regulatory submissions for regulated markets.
News coverage can also include information on Doseology’s regulatory and scientific activities, such as regulatory landscape assessments, definition of testing requirements, and planning for post-market compliance. These updates help illustrate how the company integrates regulatory science into its research and development and manufacturing validation plans.
For investors and observers interested in biotechnology-driven consumer products and oral stimulant technologies, this page offers a focused view of Doseology’s public communications. By following DOSED-related news, readers can track how the company describes its efforts to build a regulatory-ready platform, support consumer safety, and advance differentiated oral stimulant products toward commercialization.
Doseology (PINK:DOSEF; CSE:MOOD) appointed Larry Latowsky as director and Executive Chairman, effective February 18, 2026. The company granted 4,000 RSUs (36-month monthly vesting) and 6,000 PSUs tied to performance milestones. Doseology positions itself to scale precision oral stimulant delivery with strengthened governance and capital-markets expertise.
Latowsky brings pharmacy retail, manufacturing, and deal experience, including leadership roles at Katz Group and involvement in a ~C$3 billion transaction with McKesson.
Doseology (DOSED) filed its Annual Information Form (AIF) for the fiscal year ended June 30, 2025 on SEDAR+ to consolidate disclosure on business, strategy, risk factors, governance, and capital structure. The AIF aims to improve investor transparency and accessibility by combining information previously spread across multiple documents. The filing does not announce any financing or offering and is process-driven to maintain disclosure readiness and potential short-form prospectus eligibility under NI 44-101.
Doseology (ticker: DOSED) announced a strategic partnership with McKinney Regulatory Science Advisors to advance regulatory execution and commercial readiness for Doseology's oral pouch product portfolio. McKinney will advise on formulation strategy, data generation, Pre-market Tobacco Product Application (PMTA) preparation, labeling, and post-market compliance to support nicotine and nicotine-analogue pouch formats. The engagement aims to accelerate FDA pathway navigation, align R&D and manufacturing validation with regulatory expectations, strengthen IP and dose-consistency controls, and establish post-market surveillance and adverse-event reporting frameworks.
The collaboration is positioned to move Doseology from development toward regulated-market readiness while emphasizing consumer safety and regulatory-aligned product design.